Javascript must be enabled to continue!
Evolution of β-lactamase mediated cefiderocol resistance
View through CrossRef
ABSTRACT
Cefiderocol is a novel siderophore β-lactam with improved hydrolytic stability toward β-lactamases, including carbapenemases, achieved by combining structural moieties of two clinically efficient cephalosporins, ceftazidime and cefepime. Consequently, cefiderocol represents a treatment alternative for infections caused by multi-drug resistant Gram-negatives. Using directed evolution on a wide variety of different β-lactamases, such as KPC-2 and CTX-M-15 (Ambler class A), NDM-1 (class B), CMY-2 (class C) and OXA-48 (class D), we studied the role of cefiderocol during β-lactamase-mediated resistance development. First, we investigated how the expression of different β-lactamases causes changes in cefiderocol susceptibility. In a low-copy number vector, we found that OXA-48 and KPC-2 conferred non or marginal decreases in cefiderocol susceptibility, respectively. On the contrary, CMY-2, CTX-M-15 and NDM-1 substantially decreased cefiderocol susceptibility by 16-, 8- and 32-fold, respectively. Second, we determined the evolutionary potential of these enzymes to adapt to increasing concentrations of cefiderocol. Our data show that with the acquisition of only 1 to 2 mutations, all β-lactamases were evolvable to further cefiderocol resistance by 2- (NDM-1, CTX-M-15), 4- (CMY-2), 8- (OXA-48) and 16-fold (KPC-2). Cefiderocol resistance development was often associated with collateral susceptibility changes including increased resistance to ceftazidime and ceftazidime-avibactam as well as functional trade-offs against different β-lactam drugs. Taken together, contemporary β-lactamases of all Ambler classes can potentially contribute to cefiderocol resistance development and can acquire mutations allowing them to adapt to increasing cefiderocol concentration. At the same time, resistance development caused clinically important cross-resistance, especially against ceftazidime combinations.
Summary
Despite the reported higher stability of cefiderocol against β-lactamase hydrolysis, we show that the expression of β-lactamases from different Ambler classes significantly contributes to cefiderocol resistance and that these enzymes have the evolutionary potential to evolve towards increasing cefiderocol concentrations.
Title: Evolution of β-lactamase mediated cefiderocol resistance
Description:
ABSTRACT
Cefiderocol is a novel siderophore β-lactam with improved hydrolytic stability toward β-lactamases, including carbapenemases, achieved by combining structural moieties of two clinically efficient cephalosporins, ceftazidime and cefepime.
Consequently, cefiderocol represents a treatment alternative for infections caused by multi-drug resistant Gram-negatives.
Using directed evolution on a wide variety of different β-lactamases, such as KPC-2 and CTX-M-15 (Ambler class A), NDM-1 (class B), CMY-2 (class C) and OXA-48 (class D), we studied the role of cefiderocol during β-lactamase-mediated resistance development.
First, we investigated how the expression of different β-lactamases causes changes in cefiderocol susceptibility.
In a low-copy number vector, we found that OXA-48 and KPC-2 conferred non or marginal decreases in cefiderocol susceptibility, respectively.
On the contrary, CMY-2, CTX-M-15 and NDM-1 substantially decreased cefiderocol susceptibility by 16-, 8- and 32-fold, respectively.
Second, we determined the evolutionary potential of these enzymes to adapt to increasing concentrations of cefiderocol.
Our data show that with the acquisition of only 1 to 2 mutations, all β-lactamases were evolvable to further cefiderocol resistance by 2- (NDM-1, CTX-M-15), 4- (CMY-2), 8- (OXA-48) and 16-fold (KPC-2).
Cefiderocol resistance development was often associated with collateral susceptibility changes including increased resistance to ceftazidime and ceftazidime-avibactam as well as functional trade-offs against different β-lactam drugs.
Taken together, contemporary β-lactamases of all Ambler classes can potentially contribute to cefiderocol resistance development and can acquire mutations allowing them to adapt to increasing cefiderocol concentration.
At the same time, resistance development caused clinically important cross-resistance, especially against ceftazidime combinations.
Summary
Despite the reported higher stability of cefiderocol against β-lactamase hydrolysis, we show that the expression of β-lactamases from different Ambler classes significantly contributes to cefiderocol resistance and that these enzymes have the evolutionary potential to evolve towards increasing cefiderocol concentrations.
Related Results
P25 Ceftazidime/avibactam and cefiderocol use in adults in a South London Trust
P25 Ceftazidime/avibactam and cefiderocol use in adults in a South London Trust
Abstract
Background
NHS England now subsidizes pharmaceutical firms to invest in new antibiotic development. Currently, this app...
Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections
Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections
AbstractCefiderocol is a novel siderophore cephalosporin that forms a complex with extracellular free ferric iron, which leads to transportation across the outer cell membrane to e...
In Vitro Activity of Cefiderocol on Multiresistant Bacterial Strains and Genomic Analysis of Two Cefiderocol Resistant Strains
In Vitro Activity of Cefiderocol on Multiresistant Bacterial Strains and Genomic Analysis of Two Cefiderocol Resistant Strains
Cefiderocol is a new siderophore cephalosporin that is effective against multidrug-resistant Gram-negative bacteria, including carbapenem-resistant strains. The aim of this study w...
Efficacy of Cefiderocol Against Endophthalmitis Isolates
Efficacy of Cefiderocol Against Endophthalmitis Isolates
Background/Objectives: Endophthalmitis is an intraocular microbial infection that can lead to permanent blindness, even with prompt anti-microbial therapy. Multi-drug-resistant org...
Challenging Management of Postoperative Empyema: A Case Report with Literature Review
Challenging Management of Postoperative Empyema: A Case Report with Literature Review
Abstract
Introduction: Pleural empyema is the collection of pus within the pleural cavity, typically arising as a complication of pneumonia, chest trauma, thoracic surgery, or bact...
1715. In Vitro Antibacterial Activity of Cefiderocol against Difficult-to-treat Resistant (DTR) Gram-negative Pathogens in United States from SENTRY Antimicrobial Surveillance Program in 2020/2021
1715. In Vitro Antibacterial Activity of Cefiderocol against Difficult-to-treat Resistant (DTR) Gram-negative Pathogens in United States from SENTRY Antimicrobial Surveillance Program in 2020/2021
Abstract
Background
Difficult-to-treat resistant (DTR) isolates are defined as resistance to all first-line high-efficacy, low-t...
Cefiderocol as an alternative antibiotic therapy for treating severe Stenotrophomonas maltophilia infections
Cefiderocol as an alternative antibiotic therapy for treating severe Stenotrophomonas maltophilia infections
AbstractStenotrophomonas maltophilia has emerged as an opportunistic pathogen that causes life-threatening hospital-acquired infections. This microorganism possesses a diverse arra...
1734. Susceptibility of Cefiderocol between US Census Regions against Gram-Negative Organisms collected from the SENTRY Surveillance Program: 2020-2021
1734. Susceptibility of Cefiderocol between US Census Regions against Gram-Negative Organisms collected from the SENTRY Surveillance Program: 2020-2021
Abstract
Background
Cefiderocol (CFDC) is a siderophore-conjugated cephalosporin with broad activity against Gram-negative (GN) ...

